PRESS RELEASES

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary OpGen Announces Date of Third Quarter 2017 Financial Results Conference Call
GAITHERSBURG, Md. , Oct. 26, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced that it will report its third quarter 2017 financial results after close of market on Tuesday, November 7, 2017 . OpGen’s management team will host a live conference call and webcast at 4:30 p.m.
View HTML
Toggle Summary OpGen Awarded CDC Contract to Develop Clinical Support Tools for Antimicrobial Stewardship and Infection Control
GAITHERSBURG, Md. , Oct. 23, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced that it has been awarded a contract from the Centers for Disease Control and Prevention (CDC) to develop smartphone-based clinical decision support solutions for antimicrobial stewardship (AMS) and
View HTML
Toggle Summary OpGen to Present at Dawson James Securities 3rd Annual Small Cap Growth Conference
GAITHERSBURG, Md. , Oct. 13, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced that Evan Jones , the Company’s Chairman and Chief Executive Officer, will present a corporate overview at the Dawson James Securities 3rd Annual Small Cap Growth Conference on Thursday, October 19, 2017
View HTML
Toggle Summary OpGen to Present at the Ladenburg Thalmann 2017 Healthcare Conference
GAITHERSBURG, Md. , Sept. 20, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced that Evan Jones , the Company’s Chairman and Chief Executive Officer, will present a corporate overview at the Ladenburg Thalmann 2017 Healthcare Conference on Tuesday, September 26, 2017 at 4:00 p.m.
View HTML
Toggle Summary OpGen Data on New Rapid Gene Test and Antibiotic Susceptibility Prediction Algorithms Presented at the 2017 ASM/ESCMID Conference
GAITHERSBURG, Md. , Sept. 08, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced that the Company presented study results on the company’s new rapid test in development, the Acuitas® AMR Gene Panel u5.47, and the Acuitas Lighthouse® Knowledgebase for prediction of antibiotic
View HTML
Toggle Summary OpGen to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
GAITHERSBURG, Md. , Sept. 06, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced that Evan Jones , the Company’s Chairman and Chief Executive Officer, will present a corporate overview at the Rodman & Renshaw 19th Annual Global Investment Conference on Monday, September 11, 2017 at
View HTML
Toggle Summary OpGen Reports 2017 Second Quarter Financial Results and Provides Business Update
Affirms plans to launch first Acuitas® Rapid Test in first half of 2018 Conference call begins at 4:30 p.m. Eastern time today GAITHERSBURG, Md. , Aug. 08, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) reports financial and operational results for the three and six months ended June 30, 2017 ,
View HTML
Toggle Summary OpGen Announces Date of Second Quarter 2017 Financial Results Conference Call
GAITHERSBURG, Md. , Aug. 02, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced that it will report its second quarter 2017 financial results after close of market on Tuesday, August 8, 2017 . OpGen’s management team will host a live conference call and webcast at 4:30 p.m.
View HTML
Toggle Summary OpGen Announces Closing of $10 Million Public Offering
GAITHERSBURG, Md. , July 19, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) announces the closing of its previously announced public offering of 18,164,195 units at $0.40 per unit, and 6,835,805 pre-funded units at $0.39 per pre-funded unit, raising gross proceeds of approximately $10 million .
View HTML
Toggle Summary OpGen Announces Pricing of $10.0 Million Public Offering
GAITHERSBURG, Md. , July 13, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) announces the pricing of a public offering of an aggregate of 25,000,000 units. Each unit is comprised of one share of common stock (or common stock equivalent) and one common warrant to purchase one share of common
View HTML